Upgrade to SI Premium - Free Trial

Jefferies: Sarepta (SRPT) sNDA filings to set stage for 25% stock move on FDA decision

March 19, 2026 10:57 AM
Jefferies analyst Andrew Tsai reiterated a Buy rating and $30.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments